GlassScriptPhysician profile
Amish Patel
NPI 1700698008
$1,120.17
in general payments reported to CMS, 2019-2025
12 companies · $1,120 in 2025
The $1,120 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.86 | 2025 | Xifaxan |
| Janssen Biotech, INC. | $149.41 | 2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $141.34 | 2025 | |
| Genzyme Corporation | $130.18 | 2025 | |
| Qol Medical, LLC | $113.31 | 2025 | Sucraid |
| Vivus LLC | $97.84 | 2025 | Pancreaze |
| Ipsen Biopharmaceuticals, INC | $68.93 | 2025 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $54.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.49 | 2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $29.09 | 2025 | Dupixent |
| Aimmune Therapeutics, INC. | $28.64 | 2025 | Vowst |
| Novo Nordisk INC | $17.08 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amish Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.